Predicting Opportunity in Emerging Therapies
The advent of groundbreaking therapies in the metabolic sector, including GLP-1, offers substantial opportunities for pharmaceutical companies, yet accurately estimating the size of these emerging markets, marked by significant unmet clinical needs, presents distinct challenges.
The emergence of novel therapies, particularly in the metabolic space, presents valuable opportunities for drug manufacturers, who have strategically invested in these areas. However, accurately sizing these nascent markets, often characterised by well-documented unmet clinical needs, poses unique challenges.
This paper, "Predicting Opportunity in Emerging Therapies: Market Sizing Insights from the GLP-1 and Metabolic Arena," explores these challenges using the glucagon-like peptide-1 (GLP-1) market as a prime example. It highlights the importance of a comprehensive approach to market sizing, moving beyond epidemiological data to incorporate prescription rates, access considerations, stakeholder perceptions, and real-world treatment data.
The paper provides valuable guidance for navigating these complex markets, emphasising the need for robust primary market research, expert consultation, and a deep understanding of stakeholder perceptions. By addressing potential pitfalls and offering practical strategies, this paper equips manufacturers with the tools to confidently evaluate opportunities and make informed decisions in these evolving therapeutic areas.
Ipsos’ GLP-1 Market Sizing Study, which gauges caseload and GLP-1 volume usage across a variety of clinician stakeholders, will be available in Q4 ’24. Contact Ramya Logendra to learn more.
